Ocain Tim 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2019
Insider Transaction Report
Form 4
Ocain Tim
Senior Vice President
Transactions
- Tax Payment
Common Stock
2019-02-12$88.88/sh−4,580$407,070→ 17,547 total - Award
Common Stock
2019-02-12+4,000→ 12,127 total - Award
Common Stock
2019-02-12+10,000→ 22,127 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.